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Abstract
Cell therapies are potential alternatives to organ transplantation for liver failure or dysfunction but
are compromised by inefficient engraftment, cell dispersal to ectopic sites, and emboli formation.
Grafting strategies have been devised for transplantation of human hepatic stem cells (hHpSCs)
embedded into a mix of soluble signals and extracellular matrix biomaterials (hyaluronans, type
III collagen, laminin) found in stem cell niches. The hHpSCs maintain a stable stem cell
phenotype under the graft conditions. The grafts were transplanted into the livers of immuno-
compromised murine hosts with and without carbon tetrachloride treatment to assess the effects of
quiescent versus injured liver conditions. Grafted cells remained localized to the livers resulting in
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a larger bolus of engrafted cells in the host livers under quiescent conditions and with potential for
more rapid expansion under injured liver conditions. By contrast, transplantation by direct
injection or via a vascular route resulted in inefficient engraftment and cell dispersal to ectopic
sites. Transplantation by grafting is proposed as a preferred strategy for cell therapies for solid
organs such as liver.
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Patients with severe liver disease are currently managed by orthotopic liver transplantation
(OLT). Due to the paucity of available liver donors and morbidity associated with this
surgical procedure, alternative therapies are under investigation. These include liver cell
therapies in which liver cell suspensions are transplanted by a vascular route or by direct
injection into the liver with hopes of restoring liver functions in the recipient patients (1, 2).
Mature liver cell transplantation is emerging as an alternative “bridge” support for patients
waiting for a donor organ (3, 4). However, mature hepatocytes are limited by short-term
survival, proliferate poorly both in vitro and in vivo, and are difficult to cryopreserve (5–8).
To date, clinical trials of liver cell therapies have employed primarily freshly isolated,
mature hepatocytes. Despite clinical improvements in patients, significant problems have
arisen due to (i) inefficient engraftment, (ii) death or ectopic distribution of cells that didn’t
engraft in the target tissue, (iii) emboli formation, (iv) immunological rejection, and (v)
transient effects of transplanted cells.
Transplantation of stem and progenitor cell populations, rather than mature hepatocytes, has
been recently investigated, exploiting their known proliferative potential. Stem/progenitor
cells are minimally immunogenic and readily cryopreserved, but are small and engraft with
lower efficiency than the larger mature cells when injected by a vascular route (6, 9, 10).
Engraftment is improved if cells are injected directly into the tissue or via the hepatic artery,
resulting in up to ~20–30% engrafting efficiency(11). Clinical trials with transplantation of
fetal liver-derived cells expressing epithelial cell adhesion molecule (EpCAM), comprising
both human hepatic stem cells (hHpSCs) and their descendents, hepatoblasts (hHBs), have
revealed no evidence of emboli formation, no need for immunosuppression, improved
MELD scores, much longer survival of seriously ill patients, and improved liver functions in
all transplanted patients (11).
We propose that clinical programs of liver cell therapies will be best accomplished using
stem/progenitor cells in combination with a strategy that optimizes delivery and retention of
the cells in the target tissue. A way of achieving cell retention in cell therapies involves
grafting strategies by embedding cells in biomaterials that concentrate cells in the target
tissue and provide a microenvironment conducive to survival, proliferation, vascularization,
and integration into the tissue (12). Optimized grafts for human hepatic stem/progenitors are
most likely those using extracellular matrix components and soluble factors found in the
liver’s stem cell niches, the canals of Hering (13).
Hyaluronic acid, or hyaluronan (HA), is a non-sulfated glycosaminoglycan (GAG) that
makes up a significant portion of the extracellular matrix chemistry of stem cell niches. In
these niches, HA is non-covalently associated with laminins, collagens dominant in fetal
tissue (e.g. type III collagen), and forms of chondroitin sulfate proteoglycans (CS-PGs) that
have minimal sulfation (14, 15). HA is more abundant during cellular expansion/
proliferation events such as embryogenesis, wound repair, and organ regeneration (16–18),
including hepatic regeneration (19). The chemical structure of HA is conserved across all
Turner et al. Page 2













species, is biocompatible and does not elicit inflammatory, immunologic or toxic responses,
making HA an attractive biomaterial in grafting strategies to deliver and retain cells in a
regenerative niche graft (20–22). Other matrix components and soluble signals needed for
such a graft have been defined in multiple investigations assessing the effects on expansion
and differentiation of hHpSCs and hHBs, and include type III collagens and laminins (14,
23, 24).
There are numerous reports about isolation, purification, and characterization of hHpSCs
and hHBs found within human livers of all donor ages (13, 25). These two subpopulations of
multipotent cells have overlapping but distinguishable antigenic profiles. Both express
EpCAM, cytokeratins (CK) 8, 18 and 19, CD133 (prominin), Hedgehog proteins (Indian and
Sonic), CXCR4, SOX 17, and SOX 9. The hHpSCs express neural cell adhesion molecule
(NCAM) that is absent in hHBs; hHBs express intercellular adhesion molecule (ICAM-1),
α-fetoprotein (AFP) and cytochrome P450 A7, all being absent in hHpSCs (13, 14, 25–27).
We have established completely defined ex vivo conditions to maintain hHpSCs in culture
as self-replicating cells versus lineage restriction to hHBs or to hepatocytic or
cholangiocytic phenotypes (14, 24, 28, 29).
In this study, we corroborate the findings in our prior studies that hHpSCs can be cultured
and expanded in HA using combinations of appropriate matrix biomaterials and soluble
signals that mimic the liver’s stem cell niche. We also show that HA–based grafts containing
hHpSCs can be transplanted into hosts, remain localized with minimal or no distribution to
ectopic sites, and dramatically improve engraftment efficiency in the target organ over
current cell transplantation approaches.
Methods
Hepatic Stem Cell Culture Conditions
Fetal human liver cells were suspended into a serum-free, hormonally defined medium,
Kubota’s medium (KM), tailored for stem/progenitors from endodermal tissues (23). Freshly
isolated fetal liver cells were plated at 4,000–8,000 cells/cm2 on tissue culture plastic
(Becton-Dickinson, Franklin Lakes, N.J.). These culture conditions are not conducive to
survival of mature parenchymal or mature mesenchymal cells but only of stem/progenitors
from both parenchymal and mesenchymal cell lineages. Cells were plated with KM with
10% fetal bovine serum (FBS) for up to 24 hrs to facilitate attachment. Use of serum-free
conditions was essential to keep the hHpSCs and their mesenchymal cell partners, the
angioblasts, stable and with the requisite paracrine signaling (14) enabling them to self-
replicate. Serum-free KM was changed every 3–4 days. Typical plates have single cells and
small clusters of cell that adhere after the initial 24 hrs. Colonies began to appear after 1–2
weeks.
Preparation of Hyaluronans with and without other matrix components
All hyaluronan materials are from Glycosan Biosciences (Salt Lake City, UT; now a
subdivision of BioTime, Alameda, CA), and consist of thiol-modified carboxymethyl HA
(or CMHA-S), a chemically modified HA derivative with disulfide bridges for cross-linking.
The cross-linking is initiated by a PEGDA crosslinker and the level of crosslinking activity
and stiffness can be regulated by the amount of PEGDA added(20, 21, 24, 30–33), proven to
be a variable in regulating the stem cell fate. The hydrogel substrata were constructed by
dissolving dry reagents in KM to give a 2.0% solution (weight/volume) for the HA gels, and
the PEGDA crosslinker was dissolved in KM to give a 4.0% weight/volume solution, and
allowed to incubate at 37°C to dissolve. Collagen III and laminin from Sigma (St. Louis,
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MO) were used at a concentration of 1.0 mg/ml. A ratio of 1:4 was applied to blend the
cross-linker and hyaluronans.
Cell matrix culture conditions
After three weeks in culture, stem cell colonies, approximating 3000–5,000 cells/colony,
were picked and put into suspension. Cell suspensions of 200,000 cells were then combined
with hyaluronan-matrix mix. PEGDA cross-linker was added, and the cell matrix material
immediately added to wells in a 4-well chamber slide. Once the gel set, an equal amount of
Kubota’s Medium was added to the top of the well. Cultures were then maintained for a
period of 21 days, with medium changes every 48 hrs. Multiple runs were performed with
different liver samples to ensure consistency.
In vivo engraftment with direct injection strategies
Athymic nude, male mice, aged 8–12 weeks, were bred in house at the UNC Animal Care
Facility. Animals received care according to the Division of Laboratory Animal Medicine,
UNC-CH guidelines, approved by AALAC. All protocols regarding animal care and use
were approved by IACUC. Freshly isolated hepatic progenitors were infected for 4 hrs at
37°C with a luciferase-expressing adenoviral vector at 50 POI (Ad-CMV-Luc, Vector
Biolabs, Philadelphia, PA). The vector provides intense expression of luciferase for at least
48 hrs and up to 72 hrs. By 72 hrs or soon thereafter, its expression is terminated by
silencing mechanisms involving methylation of the promoter (34).
Mice (8–12 weeks) were anesthetized using Ketamine (90–120 mg/kg, Bioniche Pharma,
Lake Forrest IL), and Xylazine (10mg/kg, Akorn, Decatur, IL). Survival surgery was
performed, opening the abdomen and slowly injecting 1.5 × 106 cells directly into the liver
lobe, via cell suspension or grafted using HA hydrogels crosslinked with PEGDA, injected
intrahepatically into the front liver lobe. The incision site was closed, and animals were
given 0.1 mg/kg Buprenorphine (Reckitt Benckiser Pharmaceuticals, Richmond, VA) every
12 hrs for 48 hrs. Past studies have indicated that transplanting mice with hHpSCs first and
then establishing liver failure results in survival of all the transplanted mice, whereas the
reverse results in significant loss of mice (25). For liver injury models, a one-time dose of
carbon tetrachloride (CCl4, Sigma-Aldrich, St Louis, MO) was administered IP at 0.6 μl/g.
Statistical analysis
Experiments were repeated at least 3 times with duplicate or triplicate samples for each
condition. Data from representative experiments are presented where similar trends were
seen in multiple trials. Results were presented as mean ± standard error of the mean.
Statistical analysis of data was performed by a one-way ANOVA. Significant findings were
followed with pair-wise t-tests corrected for multiple comparisons using the step-down
Bonferroni method.
Additional methods can be found in the online supplementary information.
Results
Hyaluronan biomaterials are permissive for survival and phenotypic stability of hHpSCs
and hHBs
The hHpSCs survived and maintained a stable stem cell phenotype for more than 3 weeks in
cultures fed Kubota’s Medium and when embedded within composite matrix biomaterials
(HA, type III collagen, laminin), conditions found in stem cell niches. In both forms of
hyaluronan hydrogels used (HA versus HA + Collagen III + laminin), mRNA expression
levels (Figure 1A) show a significant (p<0.05) fold-increase in EpCAM (7.72 ± 1.42, 9.04 ±
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1.82) and albumin (5.57 ± 0.73, 4.84 ± 0.84) when compared to cells on plastic. There was
also a significant decrease in AFP (0.55 ± 0.11, 0.17 ± 0.03), and an increase in NCAM, the
combination of which indicates that cells maintain a stem cell phenotype. When the hHpSCs
lineage restricted to hepatoblasts (hHBs), they lost NCAM, and dramatically turned on
expression of AFP (14). At the protein expression level, cells in hyaluronans with or without
other matrix components, demonstrated co-expressed EpCAM and NCAM (Figure 1B). In
hydrogels supplemented with type III collagen and laminin, the EpCAM signal was the
strongest as compared to that in HA hydrogel alone. Immunosorbent assays on regularly
collected media showed that normalized albumin, transferrin, and urea concentrations were
stably synthesized by cells in both HA hydrogel conditions (Figure 2).
Grafting improves transplantation of stem cells and with restricted localization to the
target tissue
We used Luciferin-marked cells, transplanted into livers of immuno-compromised mice, and
used bioluminescent signal acquisition to test cell localization and engraftment efficiency
with grafting versus other transplantation strategies. The marking was achieved using an
adenoviral vector, Ad-CMV-Luc, that does not integrate in the genome and provides intense
but only transient expression enabling whole animal imaging. The expression is terminated
at a time point between 48 and 72 hrs or soon thereafter due to silencing of the promoter by
methylation mechanisms (34). Long-term studies required cells permanently marked using
vectors that integrated into the genome. We used lentiviral constructs coupled either to
Green Florescent Protein (GFP) or to thymidine kinase and studied long-term, stable
localization of cells using immunofluorescence (for evaluation at histological/tissue levels)
or Positron Emission Tomography (for whole body imaging). Further descriptions of the
studies with long-term marking are provided in the online supplement.
Figure 3 shows the total flux (photons per second) detected in animals within a consistent
region of interest (ROI) containing the liver where cells were injected, either by the grafting
method or by direct injection of cells. In both healthy animals and those injured with carbon
tetrachloride (CCl4), there was a noticeable difference at 12 and 48 hrs in animals
transplanted by grafting methods versus by direct injection. The grafted animals have
transplanted cells restricted to the liver and yielding higher bioluminescent flux signals. This
can be shown through the localization and distribution of bioluminescent signals (Figures 4
and 5). By contrast, those transplanted by direct injection have transplanted cells in the liver
and with significantly lower flux signals. The data are consistent with our hypothesis that
transplantation of cells with hyaluronans enhances engraftment in the target organ. Direct
injection without hyaluronans results in loss of cells either due to distribution to ectopic sites
and/or due to loss of cell viability.
Of importance is that grafting reduced significantly the extent of ectopic cell distribution.
Cells grafted to the liver using HA hydrogels were specifically localized to the injected liver
tissue. Cells that were directly injected intra-hepatically were observed to spread throughout
the abdomen, giving a weaker signal and were not localized to the initial transplanted area of
the liver.
At day 7, tissues in CCl4-treated mice were removed and fixed for histology (Figure 6). In
mice with HA-grafts of hHpSC transplants (first panel), cells formed large masses of
transplanted cells in the areas of injection and transplantation, indicating a substantial area
of humanized liver (50% or more positive staining in the field of view). Cells transplanted
via direct injection of a cell suspension (middle panel) resulted in small aggregates dispersed
throughout the liver in the area of transplantation, and with the extent of humanization (~10–
20% in the field of view) comparable to that reported by others as summarized in a recent
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review (35). Sham, positive and isotype controls for albumin expression are also displayed
(third panel).
Complementary studies with marked cells that were transplanted by a vascular route are
described further in the online supplement. These cells were transfected with a lentiviral
construct derived from Herpes Simplex Virus (HCV) and expressing thymidine kinase (TK).
(Supplementary Figures 1 and 2). They survived in culture in Kubota’s Medium for more
than 6 months (Supplementary Figure 3). Cells were transplanted via the spleen and,
therefore via the portal vein, into the livers of mice. Post-transplantation, tissues were
imaged using positron emission tomography (PET). Findings are shown after 22 and 85 days
with signals present in the liver, lung, spleen, and kidney (Supplementary Figure 4).
Therefore, the transplanted cells survived in these ectopic sites for at least 3 months.
Discussion
Grafting protocols are compelling alternative strategies for transplantation of cells from
solid organs. Our studies dramatically demonstrate that engraftment is improved and
dispersal to ectopic sites is negligible by use of grafting, as opposed to direct injection or
delivery of cells by a vascular route. Cells transplanted by a vascular route or by direct
injection have a propensity to aggregate during intravascular administration and can result in
emboli that can be life threatening.
The advantages of using grafting strategies are especially important in transplantation of
stem cells (7–10 μm), readily lost to ectopic sites if transplanted by vascular routes,
especially if by the portal vein. Moreover, they require a distinct microenvironment for
survival, expansion and integration into the target tissue as compared to that for the mature
cells. Ongoing clinical trials of hepatic stem cell therapies (35) demonstrated that the
engraftment efficiency of mature liver cells is only ~20–30%, small stem/progenitor cells is
less than 5% when transplanted into the liver via the portal vein. Others have shown that the
efficiency can be improved to a level of ~20–30%, if the stem/progenitors are transplanted
into the hepatic artery as opposed to the portal vein (11). Even with this improvement, the
majority of the cells escape to vascular beds at ectopic sites (36). This results both in a
concern for the fate of the cells in these ectopic sites and also in a need for many more donor
cells for the transplantations, since so many are lost due to the dispersal to sites other than
the target tissue. Our findings of stem cells marked with thymidine kinase and then
monitored by PET indicate that the cells at ectopic sites can survive for months.
Grafting strategies overcome these concerns by using factors and matrix biomaterials that
can be gelled into place, and thereby restricted to the desired target tissue. Moreover, the
grafts can be tailored to optimize the microenvironment for the cells, to facilitate
vascularization and also to increase the speed of regeneration within the tissue. In vivo
luminescent imaging confirmed the enhanced localization of the cells to liver by grafting
strategies. We measured luminescent signals in both suspension and grafting methods and
showed that cells are, in fact, present within the animal in both cases, with the highest
signals occurring in grafting methods for both healthy and liver injury models. Luminescent
images enhance localization of the cells within the mouse abdomen following
transplantation into the liver. While a signal is produced by both transplantation methods, it
is clear that the cells are specifically localized to the liver lobe in grafting but dispersed in
part when injected via a vascular route.
The histology of host tissue further exemplified the consistent localization of transplanted
hHpSCs if via a grafting strategy and yielded striking evidence of potentially rapid
humanization of the livers of the immunocompromised hosts. In hosts transplanted by
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grafting strategies, cells formed large masses of cells, and cells remained localized to the
liver tissue where injected. Significant humanization of the target organ does not occur in
animals transplanted with stem cells or mature cells by direct injection or by vascular route
unless the hosts have been subjected to an injury process with major loss of pericentral cells
(4–8, 37). We found that stem cells injected by a vascular route or direct injection resulted in
smaller, more dispersed groups of cells in the host livers and accounting for less than 5% if
by vascular route(25) or up to 10% if by direct injection. This is consistent with the findings
of others testing engrafting with stem/progenitors and who have reported 2–3% engraftment
(6). The combination of in vivo imaging and tissue histology gives a macro and micro image
wholly supporting the need for grafting methods as strategies for cell transplant therapies for
cells from solid organs.
The grafting biomaterials we chose are ones that elicit optimal survival and growth of the
transplanted cells along with rapid and efficient vascularization of the graft. Ideal grafting
biomaterials for hHpSCs and hHBs include HA, type III collagen and laminin, components
found in the stem cell niche (13, 14, 25). The hHpSCs and hHBs seeded into the HA
hydrogels were found to retain their viability, their ability to divide for weeks, and their
stable stem cell and progenitor phenotypes ex vivo, facilitating the long-term survival,
proliferation and maintenance. Previous studies have shown the same hepatic functions of
cells in vivo of transplanted hHpSCs in long-term studies (25). Thus, it is anticipated that
with localized grafting of cells, cell functions will increase also over time in vivo.
Gene expression in the cells cultured in the grafting biomaterials was comparable to that of
the stem/progenitors with some interesting distinctions to the findings in cultures on plastic.
There was an increased overall expression of EpCAM(25), and at levels much higher than
that for colonies on culture plastic. Similarly, the albumin expression of cells in both HA
hydrogel conditions was higher than for cells on plastic and reflects increased functions of
hHpSCs in a 3-D environment. Thus, some patterns of gene expression were influenced
primarily by the 3D culture conditions.
Preservation of the stem/progenitor cell phenotype was the net result of the cell response to
the 3-D micro-environmental conditions used in the graft. AFP is not expressed in hHpSCs
at all, either in culture or in vivo, but is characteristic of hHBs, and its expression gradually
fades with maturation to later lineage stages (25, 26, 37). In this study, the significant
decrease in AFP expression in both HA hydrogel conditions studied can be interpreted either
that the cells remained as hHpSCs, or that they matured to later lineage stages at which AFP
is not expressed. The maintenance of NCAM, a marker of stem cells, but not mature cells,
implicates that the former interpretation is correct. This suggests that the matrix chemistry
has an influence in maintaining the hHpSC phenotype, as cultures supplemented with
collagen III and laminin in addition to the 3D hyaluronan structure also underwent decreased
AFP expression.
The rigidity of the HA hydrogels can be adjusted easily and has been shown to be a critical
variable in defining the phenotype of the cells (24, 38, 39). For these studies, the formulation
of the HA gels used was that shown to be optimal for the stem cell phenotype (26) and in
which the hydrogel rigidity was at 25 Pa, well below the rigidity level of 200 Pa found
needed to induce differentiation via mechanical forces. The interaction of the cells within
the HA hydrogels was accompanied by gradual breakdown of the gels and with some
material loss in the media changes. This biodegradation is extremely beneficial for cells
being transplanted, in that the initial microenvironment is replaced with matrix components
and soluble factors from the host tissue, allowing the graft to transition to conditions for
integration into the host tissue and then differentiation, responses needed to promote
regeneration.
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Matrix components have long been known to be primary determinants of attachment,
survival, differentiation, cytoskeletal organization, and stabilization of requisite cell surface
receptors that prime the cells for responses to specific signals. Grafting of cells using
injectable biomaterials has been successful for therapies other than liver cell therapies as
discussed here. Studies involving in situ engineered tissue, including studies of injectable
Matrigel with embryonic stem (ES) cells (40) or of skeletal myoblasts in fibrin (41) have
shown restoration of cardiac function and geometry after cardiac injury. Injectable materials
solidify in vivo and retain the geometry of the injured tissue. The matrix chemistry changes
with maturational stages, with host age, and with disease states (13). Therefore, graft
biomaterials should mimic the matrix chemistry of the particular lineage stages desired for
the graft and be biocompatible for humans. Many of the biomaterials such as Matrigel can
only be used for experimental but not clinical studies. Others, such as alginate gels, are used
for walling off cells in order to protect them from immune reactions. The use of HA
hydrogels as an injectable material for tissue engineering is possibly the most optimal of any
considered due to its neutrality with respect to effects on cells embedded into it, to its long-
lasting effect, while maintaining biocompatibility (42) and ability to minimize patient
discomfort, lower risk of infection, scar formation, and overall costs (43). Cross-linking
methods also maintain the material biocompatibility, ensure retention of the cells in the
relevant target tissue and minimize escape of cells to ectopic sites.
Grafts have proven highly successful for transplantation, with localization of hHpSCs within
the target organ, and with dramatically enhanced potential for humanization of host livers.
These methods translate readily to clinical programs, since the biomaterials of these grafts
are available. Moreover, use of hyaluronans clinically is done routinely for diverse
procedures (mostly orthopedic) and found safe in those tried to date. The method can be
used for diverse liver diseases except for endstage cirrhosis with bleeding disorders
necessitating patch grafts on the liver surface, ones now under development. Translation to
clinical programs is now underway and will be attempted in clinical trials within
approximately a year. We assume that grafting strategies will comprise diverse forms in the
near future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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EpCAM Epithelial cell adhesion molecule
HA Hyaluronic Acid(hyaluronans)
HBs Hepatoblasts
HpSCs Hepatic stem cells
ICAM Intercellular adhesion molecule
KM Kubota’s Medium
Lam Laminin
NCAM Neural cell adhesion molecule
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Figure 1. Stability of hepatic stem cell phenotype in cells cultured in biomaterials comprised of
matrix factors found in the liver’s stem cell niches
a) Gene expression in stem cell colonies cultured in Kubota’s Medium (KM) and on culture
plastic versus in cells cultured three-dimensionally (3-D) in hyaluronans or in HA
supplemented with type III collagen and laminin, all components known to be in the liver’s
stem cell niche. Expression is normalized to GAPDH, and fold changes are normalized to
those in hHpSC colonies on plastic. A significance level of p<0.05% (*) is seen that in
cultures on plastic versus those in hyaluronan conditions. That comparing the expression in
HA alone versus HA with collagen III and laminin are denoted by (**) b) Expression of
EpCAM and NCAM in 3-D HA colonies. Higher levels of EpCAM and NCAM are seen in
HA supplemented with collagen III and laminin.
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Figure 2. Hepatic Functional Assays over 18 days of 3-D cultures in Kubota’s Medium and in
matrix components found in human hepatic stem cell niches
Levels of albumin (a), transferrin (b), and urea (c) production in 3-D cultures in
hyaluronans. The levels are normalized per cell. The cells remain stable and functional over
weeks under these conditions.
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Figure 3. Total flux signal captured by Luciferin-expressing, transplanted cells in grafts of cells
in hyaluronans versus injected as a cell suspension in healthy and CCl4 -induced liver injury
models
Flux readings are normalized to those in control animals receiving no cell transplant. Much
higher flux signals are observed in grafted cells, both in the healthy and injured models,
most noticeably in the first 12 and 24 hrs post-transplant. By 72 hrs, the signal is lost in all
cases due to silencing mechanisms involving methylation of the CMV promoter in the
adenoviral vector.
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Figure 4. In vivo real time imaging of luminescent signal produced by luciferin-expressing cells
in hyaluronan grafts versus injected as a cell suspension
The signals seen in animals that were grafted are found entirely in the liver, whereas those
that were transplanted without grafting materials yielded a weaker, dispersed signal
throughout the abdominal cavity.
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Figure 5. In vivo real time imaging of luminescent signal produced by luciferin-express cells in
hyaluronan grafts versus injected as a cell suspension
Shown is a replicate experiment from that demonstrated in Figure 4. The distribution of cells
to ectopic sites, such as lungs, is evident in animals with direct injection. The loss of signal
at 72 hrs has been shown by others (34) to be due to silencing of the CMV promoter by
methylation.
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Figure 6. Humanization of host livers is facilitated by grafting strategies
Grafting of transplanted cells in biomaterials such as hyaluronans, key components in the
liver’s stem cell niche, results in localization of the transplanted cells to the target organ and
more rapid humanization of that organ. By contrast, transplantation of cell suspensions
without grafting biomaterials results in smaller numbers of human cells within the target
organ and also in human cells found at ectopic sites such as lung (data not shown).
Identification of the human cells is by immunohistochemistry for human albumin. Controls
include livers from animals that were not transplanted and human fetal liver with and
without primary antibody staining.
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